KYN-101

• Description:

  KYN-101 is a potent, selective and orally active AHR inhibitor. KYN-101 decreases the CYP1A1 mRNA expression. KYN-101 shows anti-cancer activity[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319, H320

• Target:

  Aryl Hydrocarbon Receptor

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/kyn-101.html

• Concentration:

  10mM

• Purity:

  98.03

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  CC1=C2N=C(C3=CC(F)=CN=C3)C=C(NCCC4=CNC5=C4C=CC=C5)N2N=C1

• Molecular Formula:

  C22H19FN6

• Molecular Weight:

  386.42

• Precautions:

  H315, H319, H320

• References & Citations:

  [1]Campesato LF, et al. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. Nat Commun. 2020 Aug 11;11 (1) :4011.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [2247950-73-6]